Divi’s Laboratories: March ’22 Results Update
Moneylife Digital Team 01 June 2022
In the March quarter, Divi’s Laboratories (Divi’s) clocked stellar revenue growth of 41% y-o-y (year-on-year) to Rs2,518 crore, led by strong performance in the custom synthesis segment which performed well on back of molnupiravir (COVID drug) opportunity. Custom synthesis contributed 66% of total revenue in Q4FY21-22. Generic business faced headwinds because of intense pricing pressure in the...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
Already a subscriber ? Log in
Free Helpline
Legal Credit